Profile data is unavailable for this security.
About the company
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
- Revenue in EUR (TTM)756.33m
- Net income in EUR-158.98m
- Incorporated2019
- Employees4.79k
- LocationEvotec SEEssener Bogen 7HAMBURG 22419GermanyDEU
- Phone+49 40560810
- Fax+49 4 056081222
- Websitehttps://www.evotec.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Philogen SpA | 78.72m | 45.91m | 631.65m | 193.00 | 18.99 | 6.91 | 12.64 | 8.02 | 1.14 | 1.14 | 1.96 | 3.13 | 0.5961 | 5.65 | 21.87 | 430,158.50 | 34.77 | 0.7964 | 40.11 | 0.8907 | 74.04 | 58.86 | 58.33 | 3.70 | 5.52 | -- | 0.0837 | -- | 219.91 | 42.46 | 835.14 | 100.38 | 10.46 | -- |
| Valneva SE | 179.91m | -102.16m | 747.06m | 700.00 | -- | 4.95 | -- | 4.15 | -0.5807 | -0.5807 | 1.08 | 0.8762 | 0.3729 | 1.61 | 7.13 | 258,867.60 | -21.18 | -14.46 | -28.97 | -23.62 | 45.36 | 34.12 | -56.78 | -34.54 | 1.36 | -3.61 | 0.5655 | -- | 10.32 | 6.09 | 87.93 | -- | 8.60 | -- |
| Basilea Pharmaceutica AG Allschwil | 259.26m | 79.75m | 833.36m | 180.00 | 10.89 | 6.79 | 10.18 | 3.21 | 5.23 | 5.23 | 17.03 | 8.40 | 1.08 | 1.66 | 10.57 | 1,440,305.00 | 33.21 | 7.08 | 39.78 | 11.18 | 81.04 | 82.50 | 30.76 | 9.96 | 5.67 | 31.61 | 0.4428 | -- | 32.30 | 9.19 | 642.45 | -- | 34.71 | -- |
| Gubra A/S | 353.04m | 233.80m | 854.90m | 275.00 | -- | 5.25 | -- | 2.42 | -1.03 | -1.03 | 161.54 | 74.35 | 1.50 | -- | 68.31 | 11,174,780.00 | 99.21 | -- | 190.28 | -- | 3.52 | -- | 66.22 | -- | -- | -- | 0.0709 | -- | 29.63 | -- | 18.03 | -- | -- | -- |
| Nanobiotix SA | -14.04m | -51.64m | 1.01bn | 103.00 | -- | -- | -- | -- | -1.09 | -1.09 | -0.2962 | -1.43 | -0.213 | -- | -- | -130,037.00 | -78.34 | -54.39 | -839.67 | -90.60 | -- | -- | -- | -1,326.20 | -- | -7.32 | -- | -- | -138.62 | -- | -71.62 | -- | -10.10 | -- |
| Kuros Biosciences AG | 95.70m | -5.10m | 1.08bn | 122.00 | -- | 16.22 | -- | 11.32 | -0.1218 | -0.1349 | 2.25 | 1.55 | 1.16 | 1.75 | 7.11 | 714,712.10 | -6.18 | -10.85 | -7.79 | -12.28 | 83.57 | 84.11 | -5.33 | -31.80 | 1.74 | -0.4702 | 0.0655 | -- | 129.67 | 101.59 | 62.67 | -- | 60.45 | -- |
| Inventiva SA | 13.61m | -311.07m | 1.09bn | 84.00 | -- | -- | -- | 80.22 | -3.62 | -3.62 | 0.1543 | -0.064 | 0.1247 | -- | 2.35 | 124,871.60 | -284.55 | -80.43 | -555.93 | -122.98 | -- | -- | -2,282.71 | -989.96 | -- | -0.5041 | 1.18 | -- | -47.37 | 5.62 | -66.82 | -- | 19.61 | -- |
| Idorsia Ltd | 255.20m | -129.45m | 1.09bn | 938.00 | -- | -- | -- | 4.29 | -0.6593 | -0.6593 | 1.06 | -4.88 | 0.4807 | 0.3793 | 796.27 | -- | -24.38 | -48.63 | -53.54 | -61.12 | 86.49 | -- | -50.72 | -526.39 | 0.8345 | -6.02 | 31.03 | -- | -26.17 | 36.41 | 11.47 | -- | -1.08 | -- |
| Evotec SE | 756.33m | -158.98m | 1.10bn | 4.79k | -- | 1.37 | -- | 1.45 | -0.8955 | -0.8955 | 4.26 | 4.50 | 0.4019 | 20.15 | 5.17 | 156,687.00 | -8.45 | -2.40 | -10.41 | -2.87 | 10.82 | 21.49 | -21.02 | -6.78 | 2.03 | -2.54 | 0.3772 | -- | 1.99 | 12.29 | -133.67 | -- | 32.89 | -- |
| Oxford BioMedica plc | 173.91m | -42.63m | 1.14bn | 900.00 | -- | 26.69 | -- | 6.58 | -0.3539 | -0.3539 | 1.46 | 0.3084 | 0.6556 | 5.25 | 4.25 | 175,626.00 | -16.95 | -20.23 | -23.87 | -25.48 | 44.12 | 49.36 | -25.85 | -45.03 | 1.67 | -4.81 | 0.7631 | -- | 43.84 | 14.99 | 72.58 | -- | -21.89 | -- |
| Holder | Shares | % Held |
|---|---|---|
| MAK Capital One LLCas of 09 Jan 2026 | 9.39m | 5.28% |
| T. Rowe Price International Ltd.as of 06 Mar 2025 | 8.13m | 4.57% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 5.58m | 3.14% |
| Black Creek Investment Management, Inc.as of 07 Mar 2025 | 5.56m | 3.13% |
| Global Alpha Capital Management Ltd.as of 15 Nov 2024 | 5.44m | 3.06% |
| Franklin Templeton Institutional LLCas of 07 Aug 2024 | 5.26m | 2.96% |
| T. Rowe Price Associates, Inc. (IM)as of 27 Sep 2024 | 5.18m | 2.92% |
| Connor, Clark & Lunn Investment Management Ltd.as of 04 Mar 2025 | 5.14m | 2.89% |
| Brown Capital Management LLCas of 30 Sep 2025 | 4.52m | 2.55% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 2.47m | 1.39% |
